Baijin Life Science Holdings Limited
MNNGF
$0.08
$0.000.00%
OTC PK
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 60.82% | 3.10% | -38.09% | -31.26% | -23.94% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 60.82% | 3.10% | -38.09% | -31.26% | -23.94% |
| Cost of Revenue | 21.95% | -21.97% | -54.92% | -30.67% | 2.52% |
| Gross Profit | 922.45% | 334.36% | 132.29% | -33.83% | -88.69% |
| SG&A Expenses | 58.54% | 85.85% | 140.04% | 214.01% | 401.28% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 8.34% | 17.13% | 45.43% | -3,805.19% | -459.41% |
| Total Operating Expenses | 34.36% | 0.36% | -29.47% | -7.49% | 23.51% |
| Operating Income | 64.44% | 20.76% | -247.84% | -271.30% | -192.85% |
| Income Before Tax | -41.39% | -395.49% | -198.66% | -169.81% | -142.54% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -108.88% | -451.07% | -198.84% | -169.90% | -142.54% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -191.99% | -496.02% | -186.16% | -163.73% | -142.54% |
| EBIT | 64.44% | 20.76% | -247.84% | -271.30% | -192.85% |
| EBITDA | 78.06% | 34.88% | -247.50% | -261.55% | -190.83% |
| EPS Basic | -175.00% | -400.00% | -170.00% | -155.00% | -140.00% |
| Normalized Basic EPS | -250.00% | -375.00% | -166.67% | -150.00% | -133.33% |
| EPS Diluted | -175.00% | -400.00% | -170.00% | -155.00% | -140.00% |
| Normalized Diluted EPS | -250.00% | -375.00% | -166.67% | -150.00% | -133.33% |
| Average Basic Shares Outstanding | 3.89% | 5.35% | 6.89% | 16.05% | 27.02% |
| Average Diluted Shares Outstanding | 3.89% | 5.35% | 6.89% | 16.05% | 27.02% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |